Latest news

October 22, 2020

Lokon will be presented at the Nordic-American Life Science meeting.

 

October 20, 2020

Lokon's pancreatic cancer trial was presented (interim) at the World Vaccines conference.

August 28, 2020

We are pleased to announce that Lokon is extending our collaboration with Roche to develop LOAd703 and atezolizumab combination therapy also for colorectal cancer.

 

See the press release.

 

January 28, 2020

Lokons third trial treating melanoma with LOAd703 in combination with checkpoint blockade is now open for enrollment!

January 2020

The first clinical trial data from 13 pancreatic cancer patients treated with LOAd703 and standard of care chemotherapy was presented at GI ASCO San Fransciso. The full study Arm 1 with 18 response evaluable patients will be presented later this year!

Arm 2 combining LOAd703, chemotherapy and checkpoint inhibition has begun to enroll patients.

July 3, 2019

Lokon announces a collaboration with Roche to combine LOAd703 with checkpoint blockade antibody treatments in pancreatic cancer and melanoma. See the press release.

October 20, 2018
Jessica Wenthe from Uppsala University presented Lokon Pharma's research at the European Society for Medical Oncology (ESMO) in Munich and was awarded the Best Poster in the immunotherapy session. Congratulations Jessica!

Jessica ESMO award 2018jpg

May 9, 2018
The first patient has been enrolled in the LOAd703 clinical trial in Sweden for the treatment of pancreatic, biliary, colorectal, and ovarian cancer.

January 19, 2017

Our LOAd703 clinical trial for patients with pancreatic cancer in Houston, TX, USA has now treated their first patient!

July 28, 2015

EMA has granted Lokon Pharma an orphan designation status for LOAd703 immunotherapy for the treatment of pancreatic cancer.

May 4, 2015

FDA has granted Lokon Pharma an orphan designation status for LOAd703 immunotherapy for the treatment of pancreatic cancer.